ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2021
Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 52 citations in OpenAlex.
- Long COVID-19 Enigma: Unmasking the Role of Distinctive Personality Profiles as Risk Factors.Journal of clinical medicine · 2024Article
- Epidemiological contemplation for a currently pragmatic COVID-19 health passport: a perspective.Frontiers in public health · 2024Review
- The Collateral Benefit of COVID Pandemic: Improved Pharmacological Venous Thromboembolism Prophylaxis Practices in Non-COVID Patients.International journal of general medicine · 2023Article
- Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach.Current pharmaceutical biotechnology · 2023Review
- Preadmission testing for COVID-19 as a screening strategy: a retrospective chart review from a tertiary hospital in Kenya.Infection prevention in practice · 2022Article
- Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword.Journal of medical virology · 2022Article
- Stability of SARS-CoV-2-Encoded Proteins and Their Antibody Levels Correlate with Interleukin 6 in COVID-19 Patients.mSystems · 2022Article
- Clinical and Biochemical Characteristics of COVID-19 in a Primary Care Center in the South Batinah Region of Oman.Cureus · 2022Article
- Article
- Effects of vaccination against COVID-19 on the emotional health of older adults.F1000Research · 2022Article
- SARS-CoV-2 in residential rooms of two self-isolating persons with COVID-19.Journal of aerosol science · 2022Article
- Control of airborne particles in surgical procedures during the Covid-19 pandemic: scoping review.Revista da Escola de Enfermagem da U S P · 2022Article
- Genetic variations affecting ACE2 protein stability in minority populations.Frontiers in medicine · 2022Article
- Delayed positive COVID19 nasopharyngeal test, a case study with clinical and pathological correlation.BMC pulmonary medicine · 2021Article
- Safety of COVID-19 vaccines administered in the EU: Should we be concerned?Toxicology reports · 2021Article
- AYUSH- 64: A potential therapeutic agent in COVID-19.Journal of Ayurveda and integrative medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads mainly by means of aerosols (microdroplets) in enclosed environments, especially those in which temperature and humidity are regulated by means of air-conditioning. About 30% of individuals infected with SARS-CoV-2 develop coronavirus disease 2019 (COVID-19) disease. Among them, approximately 25% require hospitalization. In medicine, cases are identified as those who become ill. During this pandemic, cases have been identified as those with a positive SARS-CoV-2 polymerase chain reaction test, including approximately 70% who were asymptomatic-this has caused unnecessary anxiety. Individuals more than 65 years old, those affected by obesity, diabetes, asthma, or are immune-depressed owing to cancer and other conditions, are at a higher risk of hospitalization and of dying of COVID-19. Healthy individuals younger than 40 years very rarely die of COVID-19. Estimates of the COVID-19 mortality rate vary because the definition of COVID-19-related deaths varies. Belgium has the highest death rate at 154.9 per 100,000 persons, because it includes anyone who died with symptoms compatible with COVID-19, even those never tested for SARS-CoV-2. The United States includes all patients who died with a positive test, whether they died because of, or with, SARS-CoV-2. Countries that include only patients in which COVID-19 was the main cause of death, rather than a cofactor, have lower death rates. Numerous therapies are being developed, and rapid improvements are anticipated. Because of disinformation, only approximately 50% of the U.S. population plans to receive a COVID-19 vaccine. By sharing accurate information, physicians, health professionals, and scientists play a key role in addressing myths and anxiety, help public health officials enact measures to decrease infections, and provide the best care for those who become sick. In this article, we discuss these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.